Atrium Therapeutics Receives $15 Million Milestone Payment from Bristol-Myers Squibb
On August 13, Atrium Therapeutics (NASDAQ:RNA) received a $15 million milestone payment from Bristol-Myers Squibb (NYSE:BMY) under their global collaboration agreement. The payment was triggered by the delivery of a lead RNA compound targeting an undisclosed cardiology indication. Under the terms of the deal, Atrium could receive up to $1.35 billion in R&D milestones and $825 million in commercial milestones, with Bristol-Myers Squibb funding all future development and commercialization. The same day also saw a regulatory win for Bristol-Myers as it received accelerated FDA approval for Zenbexus (iberdomide), the first approved CELMoD therapy. This highlights contrasting financial models between Atrium—a clinical-stage company reliant on milestone payments—and BMY, an established pharmaceutical giant with strong commercial performance and diversified revenue streams. Atrium reported a Q2 net loss of $20.18 million but holds significant cash reserves to fund its pipeline advancement.
Topics: Atrium Therapeutics Bristol-Myers Squibb FDA approval milestone payment RNA platform